The Netherlands Authority for the Consumer and Markets’ ("ACM") announced focus on drug price developments has finally come to a tangible enforcement result: a fine of almost EUR 20 million imposed on Leadiant, manufacturer of the orphan drug CDCA-Leadiant. This penalty decision follows the announcement by the ACM in 2018, repeated in2020 and 2021, that it would scrutinize over-pricing of medicines.
The prices of medicines have long been part of a public debate. In its role of the...
July 21, 2021
6 min read